Home › Learn › Glossary

Reference

The GLP-1 maintenance glossary

Researching the maintenance phase means wading through a vocabulary borrowed from endocrinology, pharmacy law, and clinical practice all at once. This glossary defines the terms you'll encounter most often — in plain English, A to Z. Bookmark it and come back whenever an article or a provider uses a word you don't recognize.

Numbers & A–C

503A compounding pharmacy. A state-licensed pharmacy that prepares medications for individual patients pursuant to a valid prescription, under section 503A of the federal Food, Drug, and Cosmetic Act. Distinct from a drug manufacturer: a 503A pharmacy compounds per-patient rather than mass-producing.

Cash-pay. Paying a provider or pharmacy directly rather than through insurance. Compounded medications are typically paid for this way because insurance formularies are built around FDA-approved products.

Compounded medication. A medication prepared for a specific patient by a licensed pharmacy, based on a prescription from a licensed provider. Compounded medications are prescription-only and not FDA-approved; the FDA does not review them for safety, effectiveness, or manufacturing quality.

Contraindication. A condition or circumstance that makes a particular treatment inadvisable for a particular person — for example, certain personal or family medical histories. Screening for contraindications is a core part of a provider's evaluation.

D–G

Discontinuation. Stopping a medication. In GLP-1 research, "discontinuation studies" examine what happens to appetite and weight after therapy ends — findings that motivated the concept of a maintenance phase.

GIP. Glucose-dependent insulinotropic polypeptide, a gut hormone involved in insulin response and appetite signaling. Tirzepatide targets both GIP and GLP-1 receptors, which is why it's called a dual agonist.

GLP-1. Glucagon-like peptide-1, a hormone released by the gut after eating. It supports insulin release, slows stomach emptying, and signals fullness to the brain. "GLP-1 medications" mimic this hormone's activity.

H–M

Health history. The medical history, current medications, allergies, and goals you share with a licensed provider so they can evaluate whether a treatment is appropriate. It only works if it's complete and honest.

Licensed provider. A clinician — physician, nurse practitioner, or physician assistant, depending on state rules — licensed to evaluate patients and prescribe in your state. A prescriber generally must hold a license in the state where you are located.

Maintenance phase. The period after active weight loss when the goal shifts from losing weight to keeping it off. Clinicians increasingly treat this as its own phase of care, with its own plan, rather than an afterthought.

N–R

Needle-free. Any administration route that doesn't involve injection — oral tablets, sublingual sprays, and similar formats. Often discussed in the context of needle fatigue, the commonly reported weariness of ongoing self-injection.

Rebound (weight regain). The return of lost weight after treatment stops. Published research suggests many patients regain a significant share of lost weight within a year of stopping GLP-1 therapy without a maintenance plan; individual results vary.

Rx-only. Available only with a prescription from a licensed provider. All compounded GLP-1 medications are Rx-only — anything offered without a prescription from a licensed provider is a red flag.

S

Satiety. The sensation of fullness that tells you to stop eating. GLP-1 activity supports satiety signaling, which is why appetite commonly returns when medication stops.

Semaglutide. A GLP-1 receptor agonist molecule used in FDA-approved injectable and oral medications, and also compounded by licensed pharmacies in other forms for individual patients when prescribed.

Sublingual. Administered under the tongue, where medication is absorbed through the thin tissue of the mouth floor. Read more about how sublingual delivery works.

T

Tapering. Reducing a medication gradually — by dose or by frequency — rather than stopping abruptly. Tapering decisions belong with a licensed provider who knows your history.

Tirzepatide. A dual GIP/GLP-1 receptor agonist molecule used in FDA-approved injectable medications, and also compounded by licensed pharmacies for individual patients when prescribed.

Titration. Adjusting a dose stepwise — usually starting low and increasing gradually — to balance effect and tolerability. Both starting and stopping GLP-1 therapy often involve titration in some form.

Transmucosal. Absorption through a mucous membrane, such as the lining of the mouth. Sublingual sprays are one transmucosal format; the term covers any route that crosses mucosal tissue rather than being swallowed and digested.

Met a term here that raises a bigger question? Bring it to your own licensed healthcare provider — our list of questions for your provider can help you prepare.